07:00 , Apr 30, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: Chimeric fusion for producting water-soluble integral membrane proteins (IMPs) in bacterial culture

Drug platforms TECHNOLOGY: Fusion proteins Expression of chimeric fusions of IMPs in bacterial culture could produce stable, water-soluble IMPs for structural and functional studies. The chimeric, tripartite fusions consisted of the target IMP linked to a truncated...
07:00 , Apr 16, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: AMPA 2 glutamate receptor (GRIA2; GLUR2); glyceraldehyde-3-phosphate dehydrogenase (GAPDH)

Autoimmune disease INDICATION: Multiple sclerosis (MS) In vitro and mouse studies suggest a peptide that disrupts GLUR2-GAPDH interactions could help treat MS. In postmortem spinal cord samples from MS patients and the mouse experimental autoimmune encephalomyelitis (EAE)...
07:00 , Jun 10, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Depression; mania Kinesin light chain 2 (KLC2); glycogen synthase kinase 3b (GSK3B); AMPA 1 glutamate receptor (GRIA1;...
07:00 , Aug 21, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Neurology ...